Skip to main content
SpringerLink
Log in

Biologic-to-biosimilar switch not a cost saver

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Financial support for this study was provided by AbbVie.

Reference

  • Gibofsky A, et al. Short-term costs associated with non-medical switching in autoimmune conditions. Clinical and Experimental Rheumatology : 25 Jun 2018. Available from: URL: http://doi.org/12709 [pii]

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Biologic-to-biosimilar switch not a cost saver. PharmacoEcon Outcomes News 808, 8 (2018). https://doi.org/10.1007/s40274-018-5123-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5123-8

Search

Navigation